{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:54:20Z","timestamp":1785858860463,"version":"3.56.0"},"reference-count":16,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hematologic malignancies, including leukemia, lymphoma, and bone marrow disorders, are complex cancers often associated with chromosomal abnormalities. The emergence of COVID-19 raised concerns about its potential to induce genomic instability, influencing the prevalence and cytogenetics of these malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluates whether the COVID-19 pandemic affected the incidence, demographics, or chromosomal abnormalities in hematologic malignancies at King Chulalongkorn Memorial Hospital, Thailand, between 2018 and 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 3,077 bone marrow samples processed for cytogenetic evaluation. Samples were categorized into pre-COVID-19 (2018\u20132019) and post-COVID-19 (2020\u20132024) periods. Trends in disease incidence, patient demographics, and chromosomal abnormalities were analyzed statistically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall incidence rates of hematologic malignancies, including leukemia, lymphoma, and bone marrow disorders, remained stable throughout the study. Male-to-female ratios and average ages of onset showed no significant changes. Except for a transient rise in chromosomal abnormalities in chronic lymphocytic leukemia during 2023, no new or recurring abnormalities were identified. The mean age of onset for various malignancy categories remained consistent across the study period, and the pandemic did not significantly alter hematologic cancer trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings indicate that the COVID-19 pandemic did not substantially affect the incidence, cytogenetics, or demographics of hematologic malignancies. These results provide reassurance about the resilience of diagnostic and monitoring systems during the pandemic. Further studies are recommended to explore potential long-term implications of COVID-19 on hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/abm-2026-0022","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:59:13Z","timestamp":1785531553000},"page":"194-201","source":"Crossref","is-referenced-by-count":0,"title":["A comprehensive analysis of the incidence of chromosomal abnormalities in hematologic malignancies post-COVID-19 outbreak in King Chulalongkorn Memorial Hospital, Thailand"],"prefix":"10.2478","volume":"20","author":[{"given":"Montakarn","family":"Tansatit","sequence":"first","affiliation":[{"name":"Cytogenetic laboratory, Center for Medical Diagnostic Laboratories , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"},{"name":"Department of Anatomy, Faculty of Medicine , Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutcharee","family":"Jongpornchai","sequence":"additional","affiliation":[{"name":"Cytogenetic laboratory, Center for Medical Diagnostic Laboratories , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"},{"name":"Department of Anatomy, Faculty of Medicine , Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwannee","family":"Songchart","sequence":"additional","affiliation":[{"name":"Cytogenetic laboratory, Center for Medical Diagnostic Laboratories , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittipornpan","family":"Krajokpap","sequence":"additional","affiliation":[{"name":"Cytogenetic laboratory, Center for Medical Diagnostic Laboratories , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"},{"name":"Department of Anatomy, Faculty of Medicine , Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hudadini","family":"Da-oh","sequence":"additional","affiliation":[{"name":"Cytogenetic laboratory, Center for Medical Diagnostic Laboratories , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"},{"name":"Department of Anatomy, Faculty of Medicine , Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2026080415000497321_j_abm-2026-0022_ref_001","doi-asserted-by":"crossref","unstructured":"Jaiswal A, Shrivastav S, Kushwaha HR, Chaturvedi R, Singh RP. Oncogenic potential of SARS-CoV-2-targeting hallmarks of cancer pathways. Cell Commun Signal. 2024; 22:447. doi: 10.1186\/s12964-024-01818-0","DOI":"10.1186\/s12964-024-01818-0"},{"key":"2026080415000497321_j_abm-2026-0022_ref_002","doi-asserted-by":"crossref","unstructured":"Wiese W, Barczuk J, Racinska O, Siwecka N, Rozpedek-Kaminska W, Slupianek A, et al. PI3K\/Akt\/mTOR signaling pathway in blood malignancies-new therapeutic possibilities. Cancers (Basel). 2023; 15:5297.","DOI":"10.3390\/cancers15215297"},{"key":"2026080415000497321_j_abm-2026-0022_ref_003","doi-asserted-by":"crossref","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023; 22:138. doi: 10.1186\/s12943-023-01827-6","DOI":"10.1186\/s12943-023-01827-6"},{"key":"2026080415000497321_j_abm-2026-0022_ref_004","doi-asserted-by":"crossref","unstructured":"Ferreira AV, Netea MG. Hematopoietic memory of severe COVID-19 infection. Cell Res. 2024; 34:187\u20138.","DOI":"10.1038\/s41422-023-00885-1"},{"key":"2026080415000497321_j_abm-2026-0022_ref_005","doi-asserted-by":"crossref","unstructured":"Jafarzadeh A, Gosain R, Mortazavi SMJ, Nemati M, Jafarzadeh S, Ghaderi A. SARS-CoV-2 infection: a possible risk factor for incidence and recurrence of cancers. Int J Hematol Oncol Stem Cell Res. 2022; 16:117\u201327.","DOI":"10.18502\/ijhoscr.v16i2.9205"},{"key":"2026080415000497321_j_abm-2026-0022_ref_006","doi-asserted-by":"crossref","unstructured":"Jahankhani K, Ahangari F, Adcock IM, Mortaz E. Possible cancer-causing capacity of COVID-19: is SARS-CoV-2 an oncogenic agent? Biochimie. 2023; 213:130\u20138.","DOI":"10.1016\/j.biochi.2023.05.014"},{"key":"2026080415000497321_j_abm-2026-0022_ref_007","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36:1703\u201319.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"2026080415000497321_j_abm-2026-0022_ref_008","doi-asserted-by":"crossref","unstructured":"Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, et al. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022; 139:2273\u201384.","DOI":"10.1182\/blood.2021014309"},{"key":"2026080415000497321_j_abm-2026-0022_ref_009","doi-asserted-by":"crossref","unstructured":"Lestringant V, Guermouche-Flament H, Jimenez-Pocquet M, Gaillard JB, Penther D. Cytogenetics in the management of hematological malignancies: an overview of alternative technologies for cytogenetic characterization. Curr Res Transl Med. 2024; 72:103440.","DOI":"10.1016\/j.retram.2024.103440"},{"key":"2026080415000497321_j_abm-2026-0022_ref_010","doi-asserted-by":"crossref","unstructured":"Cavalca F, Renso R, Zambrotta GPM, Gambacorti-Passerini C, Elli EM. Being a myeloproliferative patient in COVID-19 Era: the MYTICO Study. Front Oncol. 2021; 11:668261. doi: 10.3389\/fonc.2021.668261","DOI":"10.3389\/fonc.2021.668261"},{"key":"2026080415000497321_j_abm-2026-0022_ref_011","doi-asserted-by":"crossref","unstructured":"Baransel Kamaz A, Mullally A. COVID-19 and myeloproliferative neoplasms: some considerations. Leukemia. 2021; 35: 279\u201381.","DOI":"10.1038\/s41375-020-01070-8"},{"key":"2026080415000497321_j_abm-2026-0022_ref_012","doi-asserted-by":"crossref","unstructured":"Rapti V, Tsaganos T, Vathiotis IA, Syrigos NK, Li P, Poulakou G. New insights into SARS-CoV-2 and cancer cross-talk: does a novel oncogenesis driver emerge? Vaccines (Basel). 2022; 10:1607.","DOI":"10.3390\/vaccines10101607"},{"key":"2026080415000497321_j_abm-2026-0022_ref_013","doi-asserted-by":"crossref","unstructured":"Costa BA, da Luz KV, Campos SEV, Lopes GS, Leitao JPV, Duarte FB. Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? a case series and review of the literature. Hematol Transfus Cell Ther. 2022; 44:26\u201331.","DOI":"10.1016\/j.htct.2021.11.015"},{"key":"2026080415000497321_j_abm-2026-0022_ref_014","doi-asserted-by":"crossref","unstructured":"Panico P, Ostrosky-Wegman P, Salazar AM. The potential role of COVID-19 in the induction of DNA damage. Mutat Res Rev Mutat Res. 2022; 789:108411. doi: 10.1016\/j.mrrev.2022.108411","DOI":"10.1016\/j.mrrev.2022.108411"},{"key":"2026080415000497321_j_abm-2026-0022_ref_015","doi-asserted-by":"crossref","unstructured":"Ogarek N, Oboza P, Olszanecka-Glinianowicz M, Kocelak PSARS-CoV-2 infection as a potential risk factor for the development of cancer. Front Mol Biosci. 2023; 10:1260776. doi: 10.3389\/fmolb.2023.1260776","DOI":"10.3389\/fmolb.2023.1260776"},{"key":"2026080415000497321_j_abm-2026-0022_ref_016","doi-asserted-by":"crossref","unstructured":"Victor J, Deutsch J, Whitaker A, Lamkin EN, March A, Zhou P, et al. SARS-CoV-2 triggers DNA damage response in Vero E6 cells. Biochem Biophys Res Commun. 2021; 579:141\u20135.","DOI":"10.1016\/j.bbrc.2021.09.024"}],"container-title":["Asian Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/abm-2026-0022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:00:16Z","timestamp":1785855616000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/abm-2026-0022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,30]]},"published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.2478\/abm-2026-0022"],"URL":"https:\/\/doi.org\/10.2478\/abm-2026-0022","relation":{},"ISSN":["1875-855X"],"issn-type":[{"value":"1875-855X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}